These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants. Powell SB; Silvestri JM J Pediatr; 2019 Jul; 210():209-213.e2. PubMed ID: 30992220 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial). Wu X; Xia Y; Zhou O; Song Y; Zhang X; Tian D; Li Q; Shu C; Liu E; Yuan X; He L; Liu C; Li J; Liang X; Yang K; Fu Z; Zou L; Bao L; Dai J Trials; 2020 Jan; 21(1):125. PubMed ID: 32005282 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia. Namba F Pediatr Int; 2019 Oct; 61(10):945-950. PubMed ID: 31487104 [TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stem Cells for Severe Intraventricular Hemorrhage in Preterm Infants: Phase I Dose-Escalation Clinical Trial. Ahn SY; Chang YS; Sung SI; Park WS Stem Cells Transl Med; 2018 Dec; 7(12):847-856. PubMed ID: 30133179 [TBL] [Abstract][Full Text] [Related]
6. Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia. Ahn SY; Chang YS; Kim JH; Sung SI; Park WS J Pediatr; 2017 Jun; 185():49-54.e2. PubMed ID: 28341525 [TBL] [Abstract][Full Text] [Related]
7. Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial. Ahn SY; Chang YS; Lee MH; Sung SI; Lee BS; Kim KS; Kim AR; Park WS Stem Cells Transl Med; 2021 Aug; 10(8):1129-1137. PubMed ID: 33876883 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells and TGF-β1 in tracheal aspirate of premature infants: early predictors for bronchopulmonary dysplasia? Aly H; Mansi Y; Ez El Din Z; Gabr Metwally H; Sabry A J Perinat Med; 2019 May; 47(4):470-477. PubMed ID: 30789824 [TBL] [Abstract][Full Text] [Related]
9. Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile. Álvarez-Fuente M; Arruza L; Lopez-Ortego P; Moreno L; Ramírez-Orellana M; Labrandero C; González Á; Melen G; Cerro MJD Cytotherapy; 2018 Nov; 20(11):1337-1344. PubMed ID: 30327248 [TBL] [Abstract][Full Text] [Related]
10. Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up. Cerro Marín MJD; Ormazábal IG; Gimeno-Navarro A; Álvarez-Fuente M; López-Ortego P; Avila-Alvarez A; Arruza Gómez L; González-Menchen C; Labrandero de Lera C; Lozano Balseiro M; Moreno Gutiérrez L; Melen Frajilich G; Ramírez Orellana M; Saldaña García N; Pavón Delgado A; Vento Torres M; Cytotherapy; 2024 Jun; 26(6):632-640. PubMed ID: 38556960 [TBL] [Abstract][Full Text] [Related]
11. Low serum IGF-1 and increased cytokine levels in tracheal aspirate samples are associated with bronchopulmonary dysplasia. Yılmaz C; Köksal N; Özkan H; Dorum BA; Bağcı O Turk J Pediatr; 2017; 59(2):122-129. PubMed ID: 29276864 [TBL] [Abstract][Full Text] [Related]
12. Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study. Baker EK; Malhotra A; Lim R; Jacobs SE; Hooper SB; Davis PG; Wallace EM BMJ Open; 2019 Mar; 9(2):e026265. PubMed ID: 30826799 [TBL] [Abstract][Full Text] [Related]
13. Pilot feasibility study to detect mesenchymal stem cell biomarkers of bronchopulmonary dysplasia in the tracheal aspirate fluid of preterm infants. LaGrandeur RG; Singhal M; Bany-Mohammed F; Uy C; Koeppel R; Zaldivar F; Haddad F; Nalbandian A; Donovan P; Cooper DM; Aslam M J Neonatal Perinatal Med; 2018; 11(1):1-10. PubMed ID: 29689740 [TBL] [Abstract][Full Text] [Related]